What's the outlook for MRK's EPS in 2025?

**Merck's EPS outlook for 2025 is cautious.** Here's a detailed analysis: 1. **Company's Guidance**: Merck expects adjusted EPS for 2025 to range from $8.88 to $9.03. This is below the analyst estimate of $9.51, indicating that the company's outlook is more conservative than what analysts are expecting. 2. **Analyst Expectations**: Analysts have a more optimistic view, with an average price target of $120.80 for MRK stock, suggesting a potential upside from the current price. This implies that while analysts expect growth, they are not as bullish as Merck's guidance might suggest. 3. **Comparing with Previous Years**: Merck's EPS in 2024 was $7.65, and the company is expecting an increase in 2025, although it may not be as significant as some analysts had anticipated. The EPS is projected to increase from $7.65 to a range of $8.88 to $9.03, which is a positive trend but does not represent a substantial leap forward. 4. **Sector Performance**: Merck's performance in 2024 was strong, driven by the success of its innovative portfolio and the launch of new products. However, the guidance for 2025 reflects a more measured approach, potentially due to market conditions, competitive pressures, or internal strategic considerations. In conclusion, while Merck's EPS is expected to grow in 2025, the outlook is more conservative than what some analysts had anticipated. The company's guidance and analyst expectations suggest a moderate growth trajectory for the company's earnings.